- Home
- ACAD vs ENPH Comparison
ACAD vs ENPH Comparison
Compare ACAD & ENPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- ENPH
- Stock Information
- Founded
- ACAD 1993
- ENPH 2006
- Country
- ACAD United States
- ENPH United States
- Employees
- ACAD N/A
- ENPH N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- ENPH Semiconductors
- Sector
- ACAD Health Care
- ENPH Technology
- Exchange
- ACAD Nasdaq
- ENPH Nasdaq
- Market Cap
- ACAD 4.3B
- ENPH 4.2B
- IPO Year
- ACAD 2004
- ENPH 2012
- Fundamental
- Price
- ACAD $23.61
- ENPH $37.63
- Analyst Decision
- ACAD Buy
- ENPH Hold
- Analyst Count
- ACAD 21
- ENPH 31
- Target Price
- ACAD $29.30
- ENPH $60.86
- AVG Volume (30 Days)
- ACAD 1.9M
- ENPH 7.6M
- Earning Date
- ACAD 11-05-2025
- ENPH 10-21-2025
- Dividend Yield
- ACAD N/A
- ENPH N/A
- EPS Growth
- ACAD 615.00
- ENPH 37.10
- EPS
- ACAD 1.33
- ENPH 1.28
- Revenue
- ACAD $1,018,885,000.00
- ENPH $1,482,823,000.00
- Revenue This Year
- ACAD $14.01
- ENPH $12.60
- Revenue Next Year
- ACAD $11.72
- ENPH N/A
- P/E Ratio
- ACAD $17.82
- ENPH $29.50
- Revenue Growth
- ACAD 14.41
- ENPH 4.39
- 52 Week Low
- ACAD $13.40
- ENPH $29.89
- 52 Week High
- ACAD $26.65
- ENPH $126.19
- Technical
- Relative Strength Index (RSI)
- ACAD 39.78
- ENPH 53.07
- Support Level
- ACAD $23.70
- ENPH $36.87
- Resistance Level
- ACAD $25.90
- ENPH $39.85
- Average True Range (ATR)
- ACAD 0.74
- ENPH 1.62
- MACD
- ACAD -0.33
- ENPH 0.07
- Stochastic Oscillator
- ACAD 8.16
- ENPH 48.25
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About ENPH Enphase Energy Inc.
Enphase Energy is a global energy technology company. It delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Enphase derives a majority of revenue from the United States.